Matt Scribner Sells 2,500 Shares of Inogen, Inc (INGN) Stock

Inogen, Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $112.35, for a total transaction of $280,875.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Matt Scribner also recently made the following trade(s):

  • On Thursday, October 12th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $93.88, for a total transaction of $234,700.00.
  • On Monday, September 11th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $103.23, for a total transaction of $258,075.00.
  • On Friday, August 18th, Matt Scribner sold 2,500 shares of Inogen stock. The shares were sold at an average price of $92.45, for a total transaction of $231,125.00.

Inogen, Inc (NASDAQ:INGN) opened at $118.26 on Friday. The stock has a market cap of $2,450.00, a price-to-earnings ratio of 96.94, a price-to-earnings-growth ratio of 5.01 and a beta of 0.98. Inogen, Inc has a fifty-two week low of $60.02 and a fifty-two week high of $124.90.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.04. The firm had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business’s revenue for the quarter was up 26.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.25 EPS. analysts predict that Inogen, Inc will post 1.19 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/11/18/matt-scribner-sells-2500-shares-of-inogen-inc-ingn-stock-2.html.

INGN has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a research note on Thursday, November 9th. Needham & Company LLC restated a “buy” rating and set a $108.00 price target on shares of Inogen in a research note on Friday, September 1st. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “hold” rating and set a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Finally, Leerink Swann restated an “outperform” rating and set a $120.00 price target (up previously from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $103.14.

A number of institutional investors and hedge funds have recently bought and sold shares of INGN. Teachers Advisors LLC boosted its holdings in Inogen by 2.8% during the 1st quarter. Teachers Advisors LLC now owns 27,790 shares of the medical technology company’s stock worth $2,155,000 after acquiring an additional 749 shares during the last quarter. Legal & General Group Plc boosted its holdings in Inogen by 1.0% during the 1st quarter. Legal & General Group Plc now owns 26,820 shares of the medical technology company’s stock worth $2,078,000 after acquiring an additional 258 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Inogen by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 1,213,605 shares of the medical technology company’s stock worth $94,127,000 after buying an additional 55,802 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Inogen by 5.9% in the 1st quarter. Geode Capital Management LLC now owns 173,372 shares of the medical technology company’s stock worth $13,446,000 after buying an additional 9,586 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Inogen by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 502,412 shares of the medical technology company’s stock worth $38,967,000 after buying an additional 3,796 shares during the last quarter.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply